Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- David Minor, MD
- Target Recruit Count
- 26
- Registration Number
- NCT02913417
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Jounce Therapeutics, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT02904226
- Locations
- 🇺🇸
The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT02890329
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT02879695
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2031
- Registration Number
- NCT02872116
- Locations
- 🇯🇵
Local Institution - 0122, Minato-ku, Tokyo, Japan
🇬🇷Local Institution - 0017, Nea Kifissia, Attikí, Greece
🇵🇱Local Institution - 0016, Lublin, Poland
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Herlev Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02866383
- Locations
- 🇩🇰
Herlev & Gentofte Hospital, Herlev, Denmark
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 8
- Registration Number
- NCT02846376
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 818
- Registration Number
- NCT02834013
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT02833233
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
- Conditions
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2023-01-19
- Target Recruit Count
- 33
- Registration Number
- NCT02829931
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.